Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP627975.RADQYQ7efpu4nrwsvQ4UmRzINsKeAYu1CMRqqNZHeC8pk130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627975.RADQYQ7efpu4nrwsvQ4UmRzINsKeAYu1CMRqqNZHeC8pk130_provenance.
• NP978508.RAdJI5kRRlf06Yr4YSFWgm7nlgX0_w85Wut5OC8yKnX1I130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978508.RAdJI5kRRlf06Yr4YSFWgm7nlgX0_w85Wut5OC8yKnX1I130_provenance.
• NP913998.RAcYKYwjmnFwQG05gu648n-nT3i1j9ZMPfj5AslDO-caI130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913998.RAcYKYwjmnFwQG05gu648n-nT3i1j9ZMPfj5AslDO-caI130_provenance.
• NP627984.RAzTpJKQFe5YDMj254Oa8P1W4FWpU2ZfDA6fZ8KuFRgyQ130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627984.RAzTpJKQFe5YDMj254Oa8P1W4FWpU2ZfDA6fZ8KuFRgyQ130_provenance.
• NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627982.RAdMuH_qLJLzz_5k9a-r5nTczVotlEF-6F_fi87ihNUKI130_provenance.
• assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605967.RAkPKkRm6EumYSLifgCxOi-KW4nVfaD5Fm36FTY-hFpTQ130_provenance.
• NP873172.RAqX2v7Cn809mE0NxFmncyejizISkufFHi-N52u3rD2QA130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873172.RAqX2v7Cn809mE0NxFmncyejizISkufFHi-N52u3rD2QA130_provenance.
• NP627978.RAOIgzBaaGFtTrXZYayCwozTQU2gMoBvuXCL0JezoZeb0130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627978.RAOIgzBaaGFtTrXZYayCwozTQU2gMoBvuXCL0JezoZeb0130_provenance.
• assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP781412.RAgYi0l4Q6_A13bs9xO83Hxe2dYGdHhlsr2EzONzSuIlI130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781412.RAgYi0l4Q6_A13bs9xO83Hxe2dYGdHhlsr2EzONzSuIlI130_provenance.
• NP627981.RAqUhyD25fuWABFBC1J3aTvnD62N9Y1Lj1hDxBj7NW3Os130_assertion description "[Among patients with hematologic malignancies, long-term survivors of Hodgkin's lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP627981.RAqUhyD25fuWABFBC1J3aTvnD62N9Y1Lj1hDxBj7NW3Os130_provenance.